Tutkun A, Inanli S, Caymaz O, Ayanoğlu E, Duman D
Marmara Universitesi Hastanesi, Kulak Burun Bogaz ABD, Tophanelioglu cad. no: 13-15, 81190 Altunizade, Istanbul, Turkey.
Auris Nasus Larynx. 2001 Apr;28(2):193-6. doi: 10.1016/s0385-8146(00)00112-7.
Cardiotoxicity is a rare but serious side effect of 5-flourouracil (5-FU). The cardiotoxicity incidence of 5-FU is increasing with its frequent use in chemotherapy protocols. To explain the mechanism of this cardiotoxicity, many theories have been suggested by different authors. Most commonly, coronary artery vasospasm and flouroacetate,a toxic metabolite of 5-FU, are considered responsible for the toxicity. Ischemic symptoms and signs related to 5-FU are observed during the late phase of the administration of the drug. The close and careful monitorization of all the patients, especially the ones with pre-existent coronary artery disease, during 5-FU infusion is mandatory. Because there is not a single and effective modality of treatment or prophylaxis for 5-FU cardiotoxicity, the patients should be selected carefully for 5-FU administration and 5-FU infusion should be stopped as soon as a symptom is encountered.
心脏毒性是5-氟尿嘧啶(5-FU)一种罕见但严重的副作用。随着5-FU在化疗方案中的频繁使用,其心脏毒性发生率正在上升。为了解释这种心脏毒性的机制,不同作者提出了许多理论。最常见的是,冠状动脉痉挛和5-FU的有毒代谢产物氟乙酸被认为是造成毒性的原因。与5-FU相关的缺血症状和体征在药物给药后期出现。在5-FU输注期间,对所有患者,尤其是已有冠状动脉疾病的患者进行密切和仔细的监测是必不可少的。由于对于5-FU心脏毒性没有单一有效的治疗或预防方法,因此在选择5-FU给药患者时应谨慎,一旦出现症状应立即停止5-FU输注。